Emyria Ltd Releases Annual Financial Report for FY2026
Key points
- Revenue increased by 191% to $4,053,475
- Net loss after tax increased by 95% to $6,114,401
- National expansion of Empax clinics into four states
- Established Global Empax Partnership Program
- Government and private health insurer funding secured
Full summary
Emyria Ltd's annual financial report for the year ended 30 June 2026 shows a substantial increase in revenue to $4,053,475, up 191% from the previous year. However, the net loss after tax also rose significantly by 95% to $6,114,401. The company expanded its Empax clinics into four Australian states and launched the Global Empax Partnership Program. It also secured funding agreements with government and private health insurers, including Medibank and the Department of Veterans' Affairs.
Guidance
Emyria Ltd expects to continue its national clinic rollout and expand its Empax Centre model.
Outlook
Emyria Ltd anticipates growing clinic utilisation and scaling its Empax Centre model to meet increasing demand for advanced mental health treatments.
Summary generated by a large language model. Please interpret with care.